SIGA Technologies (SIGA) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenues were $41 million, down from $81.1 million in Q2 2025, mainly due to lower U.S. Government procurement orders and a shift in product mix.

• Product-related revenues included $24 million from U.S. IV TPOXX and $13 million from international sales, with new agreements expanding access in the MENA region.

• Net income for Q2 2026 was $12.5 million, compared to $35.5 million in Q2 2025.

• The company paid a special cash dividend of $0.60 per share in April 2026.

• Continued advancement of post-exposure prophylaxis and pediatric programs, with key milestones expected in 2027 and year-end 2026.

Financial highlights

• Q2 2026 revenues: $41 million; six-month revenues: $47.2 million.

• Q2 2026 net income: $12.5 million; six-month net income: $9 million.

• Q2 2026 EPS: $0.17; six-month EPS: $0.13.

• Cash and cash equivalents at June 30, 2026: $117.6 million, with no debt.

• Operating cash flow for H1 2026: $6.5 million.

Outlook and guidance

• Actively engaging with the U.S. government on a new multi-year procurement contract, though progress is slower due to internal changes at HHS.

• Targeting a supplemental NDA submission for oral TPOXX post-exposure prophylaxis in H1 2027; pediatric phase I results expected by year-end 2026.

• Liquidity is expected to be sufficient for at least the next 12 months.

• Management expects full-year results to be impacted by the timing and volume of government procurement orders.

• Focus remains on expanding TPOXX sales internationally and maintaining U.S. government contracts.